|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
1994-2-2
|
|
pubmed:abstractText |
The effect of interferons in the correction of thrombocytosis in chronic myeloproliferative syndromes is well known. In this study the efficacy of alpha-2b interferon in a regimen of induction followed by a phase of sequential maintenance to progressively decreasing doses was evaluated with the aim of knowing the minimum doses necessary to maintain response.
|
|
pubmed:language |
spa
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0025-7753
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
13
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
601-3
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8271861-Adolescent,
pubmed-meshheading:8271861-Adult,
pubmed-meshheading:8271861-Aged,
pubmed-meshheading:8271861-Aged, 80 and over,
pubmed-meshheading:8271861-Chronic Disease,
pubmed-meshheading:8271861-Drug Administration Schedule,
pubmed-meshheading:8271861-Female,
pubmed-meshheading:8271861-Humans,
pubmed-meshheading:8271861-Interferon-alpha,
pubmed-meshheading:8271861-Male,
pubmed-meshheading:8271861-Middle Aged,
pubmed-meshheading:8271861-Myeloproliferative Disorders,
pubmed-meshheading:8271861-Prospective Studies,
pubmed-meshheading:8271861-Recombinant Proteins,
pubmed-meshheading:8271861-Thrombocytosis
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
[Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
|
|
pubmed:affiliation |
Servicio de Hematología Clínica, Ciutat Sanitària, Universitària de Bellvitge-Hospital Duran i Reynals L'Hospitalet de Llobregat, Barcelona.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
